These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18363452)

  • 1. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.
    Taylor M; Shajahan P; Lawrie SM
    J Clin Psychiatry; 2008 Feb; 69(2):240-5. PubMed ID: 18363452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Atypical antipsychotics].
    Naber D
    Nervenarzt; 2000 May; 71(5):327-8. PubMed ID: 10846707
    [No Abstract]   [Full Text] [Related]  

  • 3. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
    Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
    Novick D; Ascher-Svanum H; Brugnoli R; Bertsch J; Hong J; Haro JM
    J Nerv Ment Dis; 2012 Jul; 200(7):637-43. PubMed ID: 22759944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
    Faries D; Ascher-Svanum H; Zhu B; Correll C; Kane J
    BMC Psychiatry; 2005 May; 5():26. PubMed ID: 15921508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current pharmacotherapy of schizophrenia].
    Bitter I
    Orv Hetil; 2004 Jan; 145(3):105-9. PubMed ID: 15027331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
    Moisan J; Grégoire JP
    Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
    Geddes J; Freemantle N; Harrison P; Bebbington P
    BMJ; 2000 Dec; 321(7273):1371-6. PubMed ID: 11099280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
    Gianfrancesco F; Pesa J; Wang RH
    J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
    BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.
    Prabhakar M; Haynes WG; Coryell WH; Chrischilles EA; Miller del D; Arndt S; Ellingrod VL; Warren L; Fiedorowicz JG
    Pharmacotherapy; 2011 Aug; 31(8):806-12. PubMed ID: 21923607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological approaches to the management of schizophrenia.
    Lambert TJ; Castle DJ
    Med J Aust; 2003 May; 178(S9):S57-61. PubMed ID: 12720524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
    Law WL; Hui HY; Young WM; You JH
    Int J Clin Pharmacol Ther; 2007 May; 45(5):264-70. PubMed ID: 17542348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A typical mood stabilizers: a "typical role for atypical antipsychotics.
    Malhi GS; Berk M; Bourin M; Ivanovski B; Dodd S; Lagopoulos J; Mitchell PB
    Acta Psychiatr Scand Suppl; 2005; (426):29-38. PubMed ID: 16104066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
    Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
    Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.
    Cooper D; Moisan J; Gaudet M; Abdous B; Grégoire JP
    Can J Psychiatry; 2005 Dec; 50(14):901-8. PubMed ID: 16494259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.